The Patent Cliff Is Here—But Business Development Is Rising to the Challenge
Imagine a blockbuster drug that has generated billions in revenue suddenly facing patent expiration. It’s a scenario that keeps pharmaceutical executives awake at night, threa…
When Blockbusters Fall, Business Development Rises: Win the Patent Cliff Read Post »
In the fiercely competitive landscape of biotech innovation, securing and maintaining market exclusivity isn’t just a strategic advantage—it’s a necessity for blockbuster success. The recent surge in GLP-1 receptor agonists, driven by their transformat…
The Patent Cliff Is Here: How Pharma Giants Are Strategically Navigating the FDA Orange Book to Maximize Profits
In the high-stakes world of pharmaceuticals, the expiration of patent protections—commonly known as the “patent cliff”—poses a seismic thre…
Profit from the Patent Cliff: ANDA Filing Trends Hidden Inside the FDA Orange Book Read Post »
In the high-stakes world of pharmaceutical innovation and market competition, timing isn’t just everything—it’s the thing. For generic drug manufacturers, understanding the intricate timeline from patent listing to at-risk launch can be the difference …
Own the Generic Entry Timeline: From Orange Book Listing to At-Risk Launch Read Post »
In the fiercely competitive world of pharmaceuticals, the battle for market dominance often hinges on more than just groundbreaking science—it’s also about strategic patent positioning. A recent deep dive by Drug Patent Watch reveals a nuanced and ofte…
Own the Market: How Brand Companies Strategically List Patents in the FDA Orange Book Read Post »
The Hidden Strategy Behind Pharma’s Sales Tactics: Playing on Fear, Not Features
In the high-stakes world of pharmaceuticals, the game isn’t just about innovation or patient outcomes—it’s often about understanding and manipulating the fears that drive …
In the rapidly evolving landscape of pharmaceutical innovation, the journey from a single pill to a comprehensive platform is no longer a distant dream—it’s becoming the new standard. Yet, many industry players are still navigating this transition with…
From Pill to Platform: The Pre-LOE Device Playbook. Read Post »
ð¨ The Future of Pharma: Transforming Pills into Platforms — Are You Ready? ð¨
In an era where innovation is the currency of competitive advantage, the traditional pharmaceutical model is being reshaped at an unprecedented pace. The latest insights…
From Pill to Platform: The Pre-LOE Device Playbook. Read Post »
In the fiercely competitive world of pharmaceuticals, the battle for market dominance isn’t just about the active pharmaceutical ingredient (API). It’s about the entire formulation — especially the excipients that make up the inactive ingredients. Yet,…
Turning Patent Losses into Profit Opportunities: How Formulation Vendors Can Maximize Revenue During the 24-Month Exclusivity Window
In the fiercely competitive pharmaceutical landscape, patent expiration often signals a looming decline in revenue, pro…
How Formulation Vendors Can Turn Loss of Exclusivity Into a 24-Month Sales Window Read Post »
Get new actionable insights and updates from BiotechBlog
